Abstract The cholinesterase inhibitors (ChE-Is) attenuate the cholinergic deficit underlying
the cognitive and neuropsychiatric dysfunctions in patients with AD. Inhibition of brain …

Alzheimer's disease (AD) is a progressive neurodegenerative disorder of the elderly,
characterised by widespread loss central cholinergic function. The only symptomatic …

Acetylcholinesterase (AChE) predominates in the healthy brain, with butyrylcholinesterase
(BuChE) considered to play a minor role in regulating brain acetylcholine (ACh) levels …

Current pharmacotherapy for Alzheimer's disease involves compounds that are aimed at
increasing the levels of acetylcholine in the brain by facilitating cholinergic …

The cholinergic hypothesis of decline in dementia, whereby deficits in learning, memory and
behavior are caused, at least in part, by decreased levels of acetylcholine (ACh) in the brain …

Cholinesterase inhibitors are the standard of care for Alzheimer's disease (AD).
Acetylcholinesterase (AChE) catalyzes the hydrolysis of the cholinergic neurotransmitter …

Abstract Alzheimer's disease (AD), a progressive neurodegenerative disorder, is
characterized by the deficits in the cholinergic system and deposition of beta amyloid (Aβ) in …

Alzheimer's Disease (AD) is the most common cause for dementia in our ageing population,
which leads to a slowly progressive, irretrievable ruination of mental function. The …

Cognitive decline, commonly first recognized as memory impairment, is a typical feature of
Alzheimer's disease (AD). Neuropathological changes in the cerebral cortex and limbic …

Alzheimer's disease (AD) is well-known as a severe neurodegeneration disease involving
complicated etiologies, and cholinesterase inhibition remain the prevailing mode of clinical …